Roivant Sciences Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019
Cash & Equivalents	1,677	2,060	2,133	2,185
Cash & Cash Equivalents	1,677	2,060	2,133	2,185
Cash Growth	-18.62%	-3.39%	-2.41%	-
Other Current Assets	121.77	86.12	54.25	33.76
Total Current Assets	1,799	2,147	2,187	2,219
Property, Plant & Equipment	92.34	86.95	77.03	73.93
Long-Term Investments	304.32	325.83	298.47	177.22
Goodwill and Intangibles	144.88	0	0	0
Other Long-Term Assets	49.48	25.82	27.2	6.66
Total Long-Term Assets	591.02	438.61	402.7	257.81
Total Assets	2,390	2,585	2,590	2,477
Accounts Payable	37.83	34.58	20.55	10.31
Deferred Revenue	0	0	5.92	0
Current Debt	52.41	11.4	12.31	7.84
Other Current Liabilities	182.21	138.39	180.18	73.97
Total Current Liabilities	272.45	184.37	218.96	92.12
Long-Term Debt	428.99	272.49	232.66	173.04
Other Long-Term Liabilities	80.58	66.84	76.06	103.19
Total Long-Term Liabilities	509.57	339.33	308.73	276.24
Total Liabilities	782.02	523.7	527.69	368.36
Total Debt	481.4	283.89	244.98	180.88
Debt Growth	69.57%	15.88%	35.43%	-
Retained Earnings	-3,772.75	-2,763.72	-1,918.46	-1,109.23
Comprehensive Income	-2.62	-0.95	1.45	-2.35
Shareholders' Equity	1,158	1,657	1,798	2,032
Net Cash / Debt	1,195	1,777	1,888	2,005
Net Cash / Debt Growth	-32.71%	-5.89%	-5.83%	-
Net Cash Per Share	1.68	2.65	3.00	9.15
Working Capital	1,526	1,962	1,968	2,127
Book Value Per Share	1.62	2.47	2.85	9.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).